PDF
Progress Toward Rubella Elimination — World Health Organization European Region, 2005–2019
Organization: United States Centers for Disease Control (CDC)Published: 2021
"In 2000, estimated coverage with the first dose of a rubella-containing vaccine (RCV1) in the World Health Organization European Region (EUR) was 60%, and 621,039 rubella cases were reported (incidence = 716.9 per 1 million population).
During 2005–2019, estimated EUR RCV1 coverage was 93%–95%. In 2019, 30 (57%) countries had achieved ≥95% RCV1 coverage. Rubella incidence declined from 234.9 cases per 1 million population in 2005 to 0.7 cases per 1 million population by 2019.
Sustaining regional rubella elimination will require maintaining high coverage with rubella-containing vaccines through routine immunization, offering supplementary rubella vaccination to susceptible adults, and maintaining high-quality surveillance.
This report updates a previous report and describes progress toward rubella and CRS elimination in EUR during 2005–2019." - United States Centers for Disease Control
Product Type: Report
Category:
Monitoring and Surveillance,Vaccine Monitoring and Surveillance,Vaccination Coverage and Goals,Outbreaks and Pandemics,Outbreaks,Vaccine Preventable Disease Surveillance,Global Surveillance,Vaccine Preventable Diseases,Communicable Diseases,Rubella Monitoring and SurveillanceVaccine Monitoring and Surveillance
Vaccination Coverage and Goals
Outbreaks and Pandemics
Outbreaks
Vaccine Preventable Disease Surveillance
Global Surveillance
Vaccine Preventable Diseases
Communicable Diseases
Rubella
LinkResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.